INTRODUCTION
LDB1 (LIM-domain-binding 1) is a highly conserved transcription cofactor that was initially identified by the ability to bind to LIM domains from LIM-only and LIM-homeodomain proteins [1] . A large number of studies in Drosophila by several laboratories have revealed several important aspects of LDB1 function [2] [3] [4] [5] [6] [7] . These studies have led to a model in which an LDB1 dimer interacts with two LIM-homeodomain transcription factors. An important aspect of this model is the importance of the proper stoichiometry of LDB1 and LIM-homeodomain factors for forming the functional tetramer. The use of gene deletions, overexpression of proteins or protein domains, and chimaeric proteins have provided evidence supporting the importance of proper stoichiometry of LDB1 and LIM homeodomain factors for forming functional tetramers. This stoichiometry can also be disrupted by the LMO (LIM-only protein) dLMO (Drosophila LMO). For instance, dLMO competes with the LIMhomeodomain factor, Apterous, for binding to LDB1, disrupting the functional tetramer [3] .
Interestingly, experiments in Drosophila have demonstrated that LDB1 is necessary for segmentation, although no LIMdomain proteins are known to be required for this process [8] . This finding raised the possibility that LDB1 might have a LIM-factor-independent function in modulation of transcription. This possibility was supported by subsequent experiments demonstrating the physical and functional interaction of LDB1 with a variety of non-LIM-containing proteins [9] [10] [11] [12] [13] [14] . The role of LDB1 as a component of transcriptional complexes, including non-LIM-domain proteins, has been demonstrated in developing mouse neurons [15, 16] . Overall there is a substantial amount of evidence suggesting that LDB1 is a component of a number of transcriptional complexes.
One of the several proteins that interacts with LDB1 is RNF12 (RING finger protein 12) [9] . RNF12 was found to act as a negative co-regulator for LDB1 by recruiting the Sin3A-containing HDAC (histone deacetylase) co-repressor complex. Subsequently RNF12 was found to be an E3 ubiquitin ligase for LMOs and LDB1 [17] . This is an interesting observation in view of the importance of LDB1 protein levels for the formation of transcriptional complexes. It was also shown that RNF12 ubiquitinates LDB1 bound to LIM-homeodomain transcription factors, leading to a cofactor exchange. Studies in Xenopus have also shown that the LIM-homeodomain factor, Xlim-1, through binding to LDB1, can suppress RNF12-mediated binding and degradation of LDB1 [18] . Single-stranded DNA-binding protein 2 has also been shown to interact with LDB1, protecting it from RNF12-mediated degradation [19] .
In the present paper we report the identification of a specific lysine residue, Lys 134 , of LDB1 as the site of RNF12-mediated ubiquitination and as a critical regulator of LDB1 stability. Somewhat surprisingly, we see stabilization of LDB1 which appears to be mediated by mono-ubiquitination in the presence of RNF12 in some cells. We observe this in several tissue culture cell lines, whereas in other cell lines we see that RNF12 expression leads to the previously observed degradation of LDB1. The monoubiquitination, stabilization and degradation activities we observe depend on the RING finger domain of RNF12. Simulating monoubiquitination by fusion of ubiquitin to LDB1 greatly stabilizes LDB1 in HEK-293 cells and this effect is also cell-specific.
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EXPERIMENTAL
Cell culture, DNA constructs and transfections HEK (human embryonic kidney)-293 cells and human breast adenocarcinoma cells (MCF7 cells) were maintained in DMEM (Dulbecco's modified Eagle's medium) containing 10 % (v/v) FBS (fetal bovine serum). A reporter gene containing three LIMhomeodomain protein-binding sites linked to a minimal TATA box and the luciferase coding sequence has been described previously [20] . Mammalian expression vectors for GAL4 fusions have been described previously [21] . Expression constructs for His 6 -tagged ubiquitin and Myc-His 6 double-tagged ubiquitin K48R were obtained from Dr Hua Lu (Indiana School of Medicine, Indianapolis, IN, U.S.A.). The coding sequences for mouse and human RNF12, human UBCH5 and UBCH8 (UBC is ubiquitinconjugating enzyme), and LDB1 were amplified by PCR using standard protocols. Mouse Rnf12 and LDB1 were both subcloned into the expression vectors, pcDNA3 and pCS2+. The products were all confirmed by automated DNA sequencing. Cells were typically transfected with a total of 2 μg of DNA and 5 μl of Lipofectamine TM 2000 (Invitrogen) in 35-mm-well plates, or 0.8 μg of DNA and 2 μl of Lipofectamine TM 2000 in 22-mm-well plates using a protocol provided by the supplier.
Real-time PCR
RNA and then first-strand cDNA were made from transfected HEK-293 cells using TRIzol ® and then SuperScriptII reverse transcriptase according to the manufacturer's instructions (Invitrogen). Real-time PCR was performed using SYBR Green reagent mixture from Applied Biosystems with the ABI Taqman 7900HT real-time PCR machine. Primers used for mouse Gapdh (glyceraldehyde-3-phosphate dehydrogenase) were: 5 -CTCTG-CCACCCAGAAGACTGT-3 and 5 -GGAAGGCCATGCCAGT-GA-3 . Primers used for FLAG-tagged mouse LDB1 were: 5 -AG-CCAAGAGAGCAGATCGGAGAAT-3 and 5 -TGCCTTGTCA-TCGTCGTCCTTGTA-3 .
Preparation of cell extracts
For immunoblotting or immunoprecipitations, cells were scraped from the culture dishes in PBS. The cells were pelleted in a microfuge and resuspended in 100 mM sodium phosphate with 0.1 % Nonidet P40. The cells were disrupted by four cycles of freeze-thaw using solid CO 2 /ethanol and 37
• C water baths. After centrifugation at 10 000 g for 5 min at 4
• C, the supernatant was saved as a whole-cell extract. For preparation of cell extracts for luciferase assays, cell monolayers were rocked for 15 min in 100 mM sodium phosphate (pH 7.8) and 1 % Triton X-100. Cell debris was removed by transferring the extract to microfuge tubes and centrifuging for 2 min.
In vitro transcription and translation
A commercially available kit (TNT SP6 High-Yield Protein Expression System, Promega) was used to express ubiquitin-fused LDB1 in vitro. A linear PCR product containing an SP6 promoter ahead of the coding sequence of epitope-tagged ubiquitin-fused LDB1 was used as a template as suggested by the manufacturer. Ubiquitin aldehyde was purchased from Calbiochem.
In vitro RNA synthesis and Xenopus injections
Ovulation was induced by injecting female frogs with human chorionic gonadotropin (Sigma). Capped synthetic mRNA was synthesized by in vitro transcription from linearized templates using a commercially available kit (MegaScript, Ambion) and injected into embryos as described previously [22] .
In vivo ubiquitination assay
The in vivo ubiquitination assay was performed as described previously [23] . Transfected cells in 35-mm wells were collected by scraping in PBS. For immunoblotting, 10 % of the cells were kept as described above. The rest of the cells were disrupted by suspension in 1 ml of 6 M guanidinium/HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 (pH 8.0), 10 mM Tris/HCl and 10 mM 2-mercaptoethanol (buffer A). A 20 μl aliquot of a 50 % slurry of Ni-NTA (Ni 2+ -nitrilotriacetate) beads from Qiagen was then added and the mixture was rotated at room temperature (22
• C) for 2 h. The beads were then washed with 1 ml of buffer A, followed by 1 ml of 8 M urea, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 (pH 8.0), 10 mM Tris/HCl and 10 mM 2-mercaptoethanol, and then 1 ml of 8 M urea, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 (pH 8.0), 10 mM Tris/HCl (pH 6.3) and 10 mM 2-mercaptoethanol. Bound proteins were eluted from the Ni-NTA beads by incubation for 5 min at room temperature with two serial 20 μl aliquots of 200 mM imidazole, 0.15 M Tris/HCl (pH 6.7), 30 % glycerol, 0.72 M 2-mercaptoethanol and 5 % SDS. Proteins bound to Ni-NTA beads were then analysed by electrophoresis on a denaturing polyacrylamide gel and immunoblotting as described below.
Antiserum, immunoprecipitations and immunoblotting
A monoclonal antibody against the FLAG epitope both free and covalently attached to agarose was obtained from Sigma. A rabbit polyclonal antiserum against LDB1 was obtained from Biovintage. A rabbit anti-AU1 antiserum and the P4D1 antiubiquitin monoclonal antibody were obtained from Covance. For immunoprecipitations, cell extracts were adjusted to contain 0.1 % Tween 20. Aliquots containing equal amounts of total protein were combined with 15 μl of a 50 % slurry of anti-FLAGagarose or rabbit anti-AU1 serum and Protein A/G-agarose. The immunoprecipitation mixtures were rotated for 2 h at 4
• C and the agarose-bound antibodies were collected by centrifugation (6000 g for 30 s at 22
• C). The agarose beads were then washed three times with 1 ml each of 10 mM Tris/HCl (pH 7.4), 150 mM NaCl, 0.1 % Tween 20 and 0.1 % Triton X-100. Proteins bound to the agarose beads were then analysed by electrophoresis on a denaturing polyacrylamide gel. For immunoblotting, proteins were transferred on to PVDF membranes (Millipore). Blocking reactions, incubation with a 1:5000 dilution of antiserum against FLAG, ubiquitin or LDB1, incubation with a 1:10000 dilution of HRP (horseradish peroxidase)-conjugated goat anti-rabbit or anti-mouse antibody (Santa Cruz Biotechnology) and incubation with chemiluminescent reagent (Amersham Renaissance) were all performed as suggested by the manufacturers.
RESULTS
Previous studies have shown that RNF12 acts as a ubiquitin ligase for LDB1 leading to degradation of LDB1 through the 26S proteasome pathway [17, 18] . Therefore it was somewhat surprising to find that expression of RNF12 in HEK-293 cells leads to an increase in the level of LDB1 protein ( Figure 1A ). This increase is dependent on the RING domain of RNF12, as a mutant RNF12 protein that abolishes zinc binding and ubiquitin ligase activity [18] has little or no effect on increasing LDB1 protein levels. In contrast, and consistent with previous reports, RNF12 expression was found to reduce LDB1 protein levels in the MCF7 cell line. The RNF12 expression vectors had little effect on and either an empty expression vector (−) or vectors coding for wild-type RNF12 (WT) or RNF12 with a mutation that inactivates ubiquitin ligase activity (Mut). Whole-cell extracts were prepared 20 h after transfection, and the extracts were resolved by denaturing PAGE, transferred on to a membrane and then incubated with FLAG antiserum to detect epitope-tagged LDB1. An HRP-labelled anti-rabbit secondary antibody was used with a chemiluminescent detection reagent to visualize the immunoreactive proteins. The immunoblots were stripped and then probed with an antibody against ERK1 as a loading control. (B) HEK-293 cells were transfected with expression vectors for LDB1-FLAG, RNF12 and empty expression vectors as indicated. At 20 h after transfection, RNA was prepared from cells. Ldb1 and Gapdh RNA were quantified by real-time PCR. Ldb1 RNA expression in each sample was normalized to Gapdh in each sample and then relative RNA levels were normalized so that the wild-type average value for the Ldb1 group was set to 1. A co-immunoprecipitation study examining the interaction of the full-length LDB1 with RNF12 in HEK-293 cells provided a useful insight. HEK-293 cells were transiently transfected with expression vectors for FLAG epitope-tagged RNF12 or RNF12 mutant and untagged LDB1. The tagged RNF12 was recovered using an anti-FLAG monoclonal antibody, and coimmunoprecipitated LDB1 was visualized by immunoblotting using a polyclonal antiserum ( Figure 2 ). In this experiment relatively large amounts of DNA were transfected and long exposure times were used to enhance detection of relatively minor components. Using these conditions, the effects of RNF12 to stabilize LDB1 were not as evident ( Figure 2 , lanes 1-4). However, these conditions did permit identification of two LDB1-immunoreactive bands that were co-immunoprecipitated with wild-type RNF12 ( Figure 2 , lane 7). One of the bands migrated as expected for full-length LDB1, and a more slowly migrating band was also detected, corresponding to addition of an approx. 9 kDa mass to LDB1. Although LDB1 was found to co-immunoprecipitate with the RNF12 mutant, the more slowly migrating band, presumably representing modified LDB1, was absent ( Figure 2 , lane 8). As RNF12 has been demonstrated previously to ubiquitinate LDB1, these findings are consistent with a role for RNF12 in ubiquitination of LDB1 in HEK-293 cells. Subsequent experiments provide evidence that this modification is ubiquitin (see below). Under these conditions in HEK-293 cells, it appears that RNF12 leads to monoubiquitination which is associated with LDB1 stabilization rather than poly-ubiquitination and degradation as occurs in other cell types [17, 18] . Interestingly, in the RNF12 co-immunoprecipitate, the more slowly migrating form of LDB1 is similar in intensity to the full-length non-modified LDB1. This contrasts with the input material, where the more slowly migrating form of LDB1 is difficult to detect and therefore must be much less abundant than the non-modified LDB1. This finding suggests that RNF12 either binds preferentially to the more slowly migrating monoubiquitinated form of LDB1 or is able to mono-ubiquitinate bound LDB1 in the immunoprecipitation. The ability of wild-type RNF12 to cause the formation of a discrete size-shifted LDB1 in HEK-293 cells suggested the possibility that enhanced levels of LDB1 are due to mono-ubiquitinationinduced protein stabilization. The ability of RNF12 to induce the appearance of a shifted LDB1 band provided an assay to identify the relevant single lysine residue or multiple lysine residues. Mutation of a unique lysine residue that is mono-ubiquitinated should abolish the shifted band. We initially tested a number of lysine mutations in the C-terminal half of LDB1 (residues 196-375). In the context of full-length LDB1, these mutations tended to have a relatively small effect on increasing LDB1 protein levels and none of the mutations substantially reduced or eliminated the more slowly migrating form of LDB1 (results not shown). Consequently, attention was changed to focus on lysine residues in the N-terminal region of LDB1. A preliminary N-terminal deletion indicated that the lysine residue at position 40 of LDB1 was not required for the RNF12-mediated shifted LDB1 band (results not shown). Therefore all of the other lysine residues within residues 1-198 of LDB1 were mutated to arginine. HEK-293 cells were transiently transfected with vectors for FLAG epitope-tagged wild-type or mutant LDB1 in the absence or presence of an RNF12 expression vector and cell extracts were immunoblotted with an anti-FLAG monoclonal antibody to detect LDB1 ( Figure 3A) . With the exception of Lys 134 , all of the lysine mutants appeared to be somewhat stabilized relative to wild-type in the absence of RNF12, and were further stabilized by co-expression of RNF12. Similar results were obtained after mutation of Lys 79 or Lys 192 to arginine (results not shown). Mutation of Lys 134 to arginine dramatically increased LDB1 protein levels relative to wild-type, and this mutant LDB1 was essentially unaffected by co-expression of RNF12 ( Figure 3A, lanes 9 and 10) . To detect the more slowly migrating form of LDB1, a long exposure of the immunoblot was used ( Figure 3B ). Under these conditions, the shifted LDB1 species, indicated by the open arrow, was visible for the wild-type LDB1 and for the mutants, except for the Lys 134 mutant. These findings provide evidence that expression of the E3 ubiquitin ligase RNF12 leads to mono-ubiquitination of Lys 134 of LDB1. Lys 134 of LDB1 is apparently the major target of RNF12-mediated ubiquitination as mutation of this residue both eliminates the more slowly migrating modified form of LDB1 and dramatically stabilizes LDB1 in HEK-293 cells. In view of the findings that RNF12 expression appears to stabilize LDB1 and RNF12 also leads to mono-ubiquitination of Lys 134 of LDB1, it is surprising that the LDB1-K134R mutant is stabilized rather than degraded. One model which would be consistent with this surprising finding would involve a role for mono-ubiquitination of Lys 134 leading to stabilization and competing with poly-ubiquitination of the same residue which would lead to degradation by the proteasome. In this model, RNF12-induced mono-ubiquitination of Lys 134 would reduce poly-ubiquitination and degradation. Similarly, mutation of Lys 134 would also block poly-ubiquitination. To determine whether the K134R mutation affects LDB1 at a post-transcriptional level, LDB1 protein and RNA expression were assessed in the same experiment ( Figure 4A ). As observed in the preceding experiment, the level of K134R mutant protein was enhanced substantially as compared with wild-type LDB1. Quantification of Ldb1 RNA ( Figure 4B ) provided evidence that the RNA encoding the K134R mutant was slightly less abundant than RNA encoding wild-type LDB1. Thus changes at a post-transcriptional level must account for the increase in LDB1 protein. To explore the possibility that the K134R mutant protein is stabilized, an experiment using cycloheximide to inhibit protein synthesis was performed ( Figure 4C ). In this experiment, less expression vector for LDB1-K134R than wildtype LDB1 was transfected in an effort to equalize the levels of the two proteins and therefore facilitate comparison of the time course of cycloheximide-induced decreases in protein levels. The results provide evidence that, following inhibition of protein synthesis, wild-type LDB1 decreases more rapidly than the LDB1-K134R. The immunoblot was subjected to quantitative analysis using an appropriately labelled secondary antibody and an IR imaging system. After 4 h of cycloheximide treatment, wild-type LDB1 decreased to 38 % of control, whereas the K134R mutant decreased to 87 % of control during the same time interval. Overall the findings suggest that mutation of Lys 134 to arginine increases LDB1 expression at a post-transcriptional level, probably involving stabilization of the protein.
A transfection assay was used to determine whether RNF12-induced modification of LDB1 Lys 134 involves ubiquitin. FLAG epitope-tagged LDB1 was expressed in HEK-293 cells in the absence or presence of RNF12 and His 6 -tagged ubiquitin. The cells were disrupted, proteins were denatured in guanidinium and the extract was subjected to Ni-NTA chromatography to isolate histidine-containing proteins. LDB1 in the eluate was identified by immunoblotting with an anti-FLAG monoclonal antibody ( Figure 5A ). Although many proteins can bind to nickelchelate resin, His 6 -tagged proteins bind strongly to the resin. Analysis of the input LDB1-FLAG again provided evidence for enhanced levels of LDB1-K134R as compared with wild-type ( Figure 5A, lanes 4-6) . In the absence of His 6 -tagged ubiquitin, there was some background binding of LDB1-FLAG to the nickel-chelate resin ( Figure 5A, lanes 7 and 10) , presumably due to the histidine content of LDB1. The more slowly migrating form of LDB1-FLAG was only detected with wild-type LDB1 in the presence of both His 6 -tagged ubiquitin and RNF12 ( Figure 5A , lane 9). The LDB1-K134R mutation abolished the more slowly migrating LDB1 immunoreactive band. These findings support the view that RNF12 causes mono-ubiquitination of LDB1 at Lys 134 . Interestingly, overexpression of ubiquitin appeared to decrease the levels of wild-type LDB1, but not the Lys 134 LDB1 mutant ( Figure 5A, lanes 1-3) . This is consistent with a model in which mono-or poly-ubiquitination of Lys 134 of LDB1 may cause either stabilization or degradation. To examine this further, the Whole-cell extracts were prepared 20 h after transfection from half of the cells and the extracts resolved by denaturing PAGE, transferred on to a membrane and then incubated with FLAG antiserum to detect epitope-tagged LDB1. An HRP-labelled anti-rabbit secondary antibody was used with a chemiluminescent detection reagent to visualize the immunoreactive proteins. The membrane was then incubated with an antibody against ERK1 as a loading control. (B) RNA was prepared from half of the transfected cells, as described in the Experimental section. Ldb1 and Gapdh RNA were quantified by real-time PCR. Ldb1 RNA expression in each sample was normalized to Gapdh in each sample and then relative RNA levels were normalized so that the wild-type average value for the Ldb1 group was set to 1.0. (C) HEK-293 cells were transfected with an expression vector for FLAG-tagged wild-type or K134R mutant LDB1. Twice as much expression vector for wild-type LDB1 was transfected in an attempt to equalize the amounts of wild-type and mutant LDB1. The next morning, cells were either untreated or treated with 25 μg/ml cycloheximide for the times indicated. Whole-cell extracts were prepared and the extracts were resolved by denaturing PAGE, transferred on to a membrane and then incubated with FLAG antiserum to detect epitope-tagged LDB1. An HRP-labelled anti-rabbit secondary antibody was used with a chemiluminescent detection reagent to visualize the immunoreactive proteins. The membrane was then incubated with an antibody against ERK1 as a loading control.
experiment was repeated using a His 6 -tagged ubiquitin-K48R. Ubiquitin Lys 48 is the major site of ubiquitin polymerization leading to proteasomal targeting [24] . Mutating this lysine residue of ubiquitin should block poly-ubiquitination and act to inhibit protein degradation. Transfection of a vector for ubiquitin-K48R was found to enhance the level of LDB1-FLAG, similar to that obtained with RNF12 [ Figure 5B , lower (input) panel, lanes [13] [14] [15] . Following expression of the mutant ubiquitin-K48R and nickel-chelate chromatography, the more slowly migrating form of LDB1 was easily detected and indeed became the major form of LDB1 ( Figure 5B, lane 15) . Expression of ubiquitin-K48R with the LDB1-K134R mutant abolished the shifted band observed with wild-type LDB1. Expression of ubiquitin-K48R should essentially act to trap LDB1 that is normally poly-ubiquitinated. The finding that LDB1-K134R mutation blocks formation of the more slowly migrating form of LDB1 provides additional evidence that Lys 134 is the major site of LDB1 ubiquitination in HEK-293 cells. These results are also consistent with a model involving mono-ubiquitination of Lys 134 in HEK-293 cells leading to LDB1 stabilization or poly-ubiquitination leading to proteasomal degradation. The findings described above are consistent with a role for Lys 134 of LDB1 as the major site of both mono-ubiquitination and poly-ubiquitination. Although several of these studies have used immunoblots to detect a slowly migrating mono-ubiquitinated form of LDB1, these immunoblots did not detect more slowly migrating forms of LDB1 representing poly-ubiquitination. Presumably poly-ubiquitinated LDB1 is degraded rapidly and therefore the poly-ubiquitinated form of LDB1 is difficult to detect. In an effort to address this issue, we used an alternative approach. HEK-293 cells were transfected with FLAG-tagged wild-type or mutant LDB1, in the absence or presence of RNF12. For this experiment, less LDB1-K134R expression vector than wild-type LDB1 vector was used in an attempt to equalize expression of wild-type and mutant LDB1. LDB1 was isolated by immunoprecipitation with a monoclonal anti-FLAG antibody. The immunoprecipitated proteins were eluted using non-denaturing conditions. This allows the bound proteins to be eluted without substantial contamination by the anti-FLAG antibody, facilitating the subsequent use of a second mouse monoclonal antibody to detect ubiquitin. The use of an antibody against ubiquitin in this experiment may enhance detection of poly-ubiquinated proteins (A) HEK-293 cells were transfected with expression vectors for LDB1-FLAG, poly-His-ubiquitin (His-UB) and AU1-RNF12 (RNF12) as indicated. At 20 h after transfection, whole-cell extracts were prepared and histidine-containing proteins were isolated under denaturing conditions by nickel-chelate chromatography. An aliquot of the whole-cell extract (5 % input) or the proteins isolated by nickel-chelate chromatography was resolved by denaturing PAGE. FLAG-tagged LDB1 was visualized by immunoblotting with an anti-FLAG monoclonal antibody. Proteins with the appropriate migration for full-length FLAG-tagged LDB1 are indicated with a closed arrow, and a more slowly migrating form of LDB1 is indicated with an open arrow. (B) HEK-293 cells were transfected with expression vectors for LDB1-FLAG, poly-His-ubiquitin-K48R (His-UB-K48R) and AU1-RNF12 (RNF12) as indicated. Histidine-containing proteins were isolated by chromatography and analysed by PAGE as described above. Closed arrows indicate migration appropriate for LDB1-FLAG; open arrows indicate the more slowly migrating form of LDB1-FLAG.
that contain multiple copies of the antigen. The eluted proteins were analysed by denaturing PAGE and immunoblot analysis using a monoclonal antibody against ubiquitin. Expression of RNF12 with wild-type LDB1 resulted in a 'ladder' of discrete ubiquitin-containing proteins of increasing sizes, probably representing poly-ubiquitinated proteins ( Figure 6, lane 3) . The immunoprecipitated proteins in this experiment were eluted using non-denaturing conditions. Therefore the poly-ubiquitinated proteins detected may be LDB1 and/or LDB1-associated proteins. The ubiquitin-containing protein ladder is greatly reduced for the LDB1-K134R mutant ( Figure 6, lane 5) , suggesting that the poly-ubiquitinated protein may indeed be LDB1. However, we cannot rule out the possibility that mutation of Lys 134 disrupts the interaction of LDB1 with another protein that is poly- The finding that RNF12-mediated mono-ubiquitination of LDB1 in HEK-293 cells is associated with increased protein levels of LDB1 suggests that this modification may play a role in stabilization of LDB1. To further test this model we prepared an expression vector for a ubiquitin-LDB1 fusion. We fused the N-terminus of LDB1 to the C-terminus of either wild-type ubiquitin or a ubiquitin mutant with the C-terminal glycine residue replaced with valine (G76V). Use of the ubiquitin-G76V mutant has been shown to produce fusion proteins resistant to de-ubiquitinating enzymes [25] . Previous studies have shown that fusions to ubiquitin destabilizes proteins, presumably by enhancing poly-ubiquitination [25] [26] [27] . In contrast with the previously observed protein destabilization, transfection of the ubiquitin-LDB1 fusion vector (AU1-UB-LDB1-FLAG) in HEK-293 cells led to increased protein levels as compared with non-fused LDB1 (AU1-LDB1-FLAG; Figure 7A ). The product of the fusion of wild-type ubiquitin to LDB1 appeared to be efficiently de-ubiquitinated, as the major protein observed had the same electrophoretic mobility as LDB1 not fused to ubiquitin ( Figure 7A, lanes 2 and 3) . Although the ubiquitin-LDB1 fusion appeared to be rapidly de-ubiquitinated, the amount of LDB1 protein was increased as compared with LDB1 produced from an expression vector for non-fused LDB1. Ubiquitin-G76V-fused LDB1 was not de-ubiquitinated and accumulated to even higher levels ( Figure 7A, lanes 2 and 4) . The observation that the wildtype ubiquitin-LDB1 fusion protein is readily de-ubiquitinated is (A) HEK-293 or MCF7 cells were transfected with an empty expression vector or an expression vector for epitope-tagged wild-type, wild-type-ubiquitin-fused or G76V-mutant-ubiquitin-fused LDB1. Whole-cell extracts were prepared 20 h after transfection from half of the cells and the extracts were resolved by denaturing PAGE, transferred on to a membrane and then incubated with FLAG antiserum to detect epitope-tagged LDB1. An HRP-labelled anti-rabbit secondary antibody was used with a chemiluminescent detection reagent to visualize the immunoreactive proteins. The membrane was then incubated with an antibody against ERK1 as a loading control. (B) RNA was prepared from half of the transfected cells as described in the Experimental section. Ldb1 and Gapdh RNA were quantified by real-time PCR. Ldb1 RNA expression in each sample was normalized to Gapdh in each sample and then relative RNA levels were normalized so that the wild-type average value for the Ldb1 group was set to 1.0. (C) HEK-293 cells were transfected with an expression vector for epitope-tagged wild-type, wild-type-ubiquitin-fused or G76V-mutant-ubiquitin-fused LDB1.
consistent with previously published reports [25, 26] . We further examined possible de-ubiquitination of the LDB1-fusion protein using ubiquitin aldehyde to inhibit de-ubiquitinating enzymes in a cell-free system [28] . Proteins were expressed using a cellfree system derived from wheat germ. In reactions programmed with RNA directing synthesis of the ubiquitin-LDB1 fusion (AU1-UB-LDB1-FLAG) the major product had the same size as reactions programmed by AU1-LDB1-FLAG RNA, offering evidence that the ubiquitin-LDB1 fusion was efficiently deubiquitinated ( Figure 8, lane 2) . Increasing amounts of ubiquitin aldehyde resulted in a product with the mobility as expected for the ubiquitin-LDB1 fusion protein. The findings with ubiquitin aldehyde provide evidence that the ubiquitin-LDB1 coding sequence directs the synthesis of a fusion protein as expected, and that this ubiquitin-LDB1 fusion protein can be efficiently deubiquinated. Quantitative PCR demonstrates that the RNA levels for the ubiquitin-fused LDB1 constructs transfected into HEK-293 cells are all similar (Figure 7B ), suggesting that changes in protein stability are responsible for the different levels of proteins observed. To test this further, we performed an experiment using cycloheximide to inhibit protein synthesis ( Figure 7C ). Fusion of wild-type ubiquitin or ubiquitin-G76V with LDB1 greatly increased the apparent half-life of the fusion protein as compared with non-fused LDB1. We did not see as much difference in degradation between wild-type ubiquitin and ubiquitin-G76V-fused LDB1 as would be expected based on differences in steadystate levels ( Figure 7A) ; this may be due to increasing cell death with longer cycloheximide treatments. The half-lives of these fusion proteins appeared to be longer than the time required for cycloheximide to cause significant cell death.
The effects of RNF12 on LDB1 stability are cell-specific, as demonstrated in Figure 1 . We tested the effects of ubiquitin fusion to LDB1 in MCF7 cells ( Figure 7A ). In contrast with what is seen in HEK-293 cells, both the wild-type and G76V ubiquitin-fused LDB1 are expressed at a similar level as non-fused LDB1. This suggests that, like the ability of RNF12 to mono-ubiquitinate and stabilize LDB1, stabilization of LDB1 by ubiquitin fusion is cellspecific.
To further test the physiological significance of Lys 134 in regulating expression of LDB1, we injected RNA for epitope-tagged wild-type and K134R Xenopus laevis LDB1 into developing Xenopus laevis embryos. Murine and Xenopus LDB1 differ at just five amino acids and Lys 134 is conserved. Embryos were injected dorsally at the four-cell stage with 4 ng of capped RNA. Embryos were collected at stage 11 and equal amounts of protein extracts were analysed by denaturing PAGE and immunoblotting with a polyclonal antiserum against LDB1 (Figure 9 ). The K134R mutant Xenopus LDB1 was found to be present at a greater amount than wild-type LDB1 (Figure 9, lanes 1 and 2) . A slightly more rapidly migrating band that is presumably endogenous LDB1 was also detected in this experiment and, as the endogenous LDB1 is expressed at approximately the same level as the LDB1-FLAG, offers evidence that tagged LDB1 is not substantially overexpressed. The endogenous LDB1 also serves as a loading control. These findings provide evidence that in a Twice as much expression vector for wild-type LDB1 was transfected in an attempt to equalize the amounts of wild-type and ubiquitin-fused LDB1. The next morning, cells were either untreated or treated with 25 μg/ml cycloheximide for the times indicated. Whole-cell extracts were prepared and the extracts were resolved by denaturing PAGE, transferred on to a membrane and then incubated with FLAG antiserum to detect epitope-tagged LDB1. An HRP-labelled anti-rabbit secondary antibody was used with a chemiluminescent detection reagent to visualize the immunoreactive proteins. The membrane was then incubated with an antibody against ERK1 as a loading control. The molecular mass in kDa is indicated on the left-hand side. A wheat-germ-based in vitro coupled transcription/translation system was used to express epitope-tagged ubiquitin-fused LDB1. All reactions contained the same reagents and template with the exception of ubiquitin aldehyde which was present at the concentrations indicated. Aliquots of the reactions were resolved by denaturing PAGE, transferred on to a membrane and then incubated with FLAG antiserum to detect epitope-tagged LDB1. An HRP-labelled anti-rabbit secondary antibody was used with a chemiluminescent detection reagent to visualize the immunoreactive proteins. The migration of a protein the appropriate size for the tagged-ubiquitin LDB1 fusion is indicated with an open arrow. The molecular mass in kDa is indicated on the left-hand side. Figure 9 Xenopus LDB1 K134R is stabilized in developing Xenopus laevis embryos cRNA (4 ng) for epitope-tagged, wild-type and K134R Xenopus laevis LDB1 was injected dorsally at the four-cell stage into developing Xenopus laevis embryos. Embryos were collected at stage 11 and equal amounts of protein extracts were analysed by denaturing PAGE and immunoblotting with a polyclonal antiserum against LDB1. The molecular mass in kDa is indicated on the right-hand side.
physiological setting, Lys 134 plays an important role in regulating expression of LDB1.
As we have found that RNF12-mediated mono-ubiquitination leads to substantial increases in LDB1 expression in HEK-293 cells, it seems likely that these changes in expression would influence the ability of LDB1 to function as a transcriptional cofactor. As mentioned previously, the stoichiometry of LDB1 to interacting transcription factors is important [2] [3] [4] [5] [6] [7] . Overexpression of LDB1 as compared with LIM-homeodomain transcription factors can inhibit transcription, presumably by disrupting the formation of tetramer complexes involving LDB1 dimers interacting with the LIM-homeodomain factors. To test this, we used a reporter gene containing three copies of the LIMhomeodomain-binding sequence from the glycoprotein hormone α-subunit promoter. The glycoprotein hormone α-subunit promoter has been shown to be activated by LIM-homeodomain transcription factors [29, 30] . HEK-293 cells were transfected with the luciferase reporter gene containing three copies of a LIM-homeodomain-binding site and a minimal promoter and expression vectors for Lhx3 and vectors encoding wild-type LDB1 or LDB1-K134R ( Figure 10 ). As expected, overexpression of wild-type LDB1 in HEK-293 cells inhibited the activity of the α-subunit reporter gene. Expression of LDB1-K134R resulted in greater inhibition of the α-subunit reporter gene, consistent with the substantially higher level of expression of the mutant protein and the inhibitory effects of LDB1 overexpression.
DISCUSSION
The present studies have used RNF12 as a tool to identify Lys 134 of LDB1 as a residue that can be modified by ubiquitination leading to changes in LDB1 protein levels. We find that mutation of Lys 134 of LDB1 to arginine has substantial effects on LDB1 levels in both cultured cells and Xenopus embryos. Combined with the finding that Lys 134 is required for both mono-ubiquitination and poly-ubiquitination of LDB1, the studies are consistent with a model in which mono-ubiquitination of Lys 134 can enhance stability of LDB1, whereas poly-ubiquitination leads to increased degradation of LDB1. The view that LDB1 mono-ubiquitination can stabilize LDB1 is supported by the observation that a fusion of ubiquitin to LDB1 causes substantial stabilization of LDB1. As LDB1 protein levels and LDB1 stoichiometry relative to binding partners is very important [2] [3] [4] 6, 7] , the ability of ubiquitination of Lys 134 to alter LDB1 levels would be expected to have important consequences for LDB1 function. In a study of the developmental expression pattern of RNF12 and LDB1 it was found that protein expression levels varied more than the nearly ubiquitous RNAs for these factors, suggesting substantial post-transcriptional regulation [31] . Cellspecific differences in regulation of LDB1 degradation are probably one of the post-transcriptional mechanisms contributing to tissue-specific differences in LDB1 protein expression. The present studies identify Lys 134 as an important residue regulating LDB1 expression and this finding provides insight into the regulation of transcriptional complexes that include LDB1.
There are a number of interesting questions about RNF12-mediated ubiquitination of LDB1 that await future studies. An interesting mechanistic question concerns the ability of RNF12 to decrease LDB1 expression in MCF7 cells and increase LDB1 expression in HEK-293 cells. Presumably there is some altered or unique component of the ubiquitination machinery that leads to this change in outcome. There is evidence that ubiquitin chain initiation and elongation are kinetically separable processes [32] which may be mediated by different E2 ubiquitinconjugating enzymes acting sequentially [33, 34] . Therefore it is possible that differences in expression of specific E2 ubiquitinconjugating enzymes in HEK-293 cells compared with MCF7 cells leads to differences in mono-ubiquitination compared with poly-ubiquintation. It has been reported that UBCH5 or UBCH8 can act as an E2 ubiquitin-conjugating enzyme for RNF12 [17, 35] . In HEK-293 cells, expression vectors for UBCH5 or UBCH8 had relatively small effects on LDB1 expression (P.W. Howard, unpublished work). A number of other E2 enzymes have been shown to interact with RNF12 [36] and these enzymes remain candidates as mediating cell-specific effects of RNF12. In addition, some E2 enzymes function with specific E3 ligase proteins, even though a physical interaction between them is not observed in typical experimental screens [37] . Thus further studies of a possible role for specific E2 enzymes in monoubiquitination of LDB1 will probably require a comprehensive analysis of E2 expression in different cells and tissues, as well as a test of functional roles through overexpression and knockdown approaches. Another possibility for tissue-specific effects of RNF12 could involve differential expression of another E3 ubiquitin ligase. Although RNF12 has been shown to be a ubiquitin ligase, it is possible that RNF12 works indirectly to recruit another protein that plays a role in direct ubiquitination of LDB1. It has been shown that RING domain proteins can interact with a second RING domain protein to enhance the ubiquitin ligase activity of the second protein [38] [39] [40] . Thus cell-specific differences in the expression of E2 or E3 enzymes might account for cell-specific differences in mono-ubiquitination.
Similarly, the mechanisms permitting mono-ubiquitination to stabilize LDB1 are unknown. One possibility could involve interaction of ubiquitin-binding proteins with mono-ubiquinated LDB1. This binding could act to block poly-ubiquitination [41] . It is conceivable that the physical interaction of RNF12 with LDB1 under some circumstances blocks poly-ubiquitination. Interestingly, although RNF12 expression increases the level of LDB1 protein, only a relatively small fraction of LDB1 appears to be mono-ubiquitinated. How can this small amount of modified LDB account for substantial changes in LDB1 expression? It should be noted that this observation is not without precedent. There are other examples of regulation by ubiquitin or ubiquitinlike proteins that appear to involve modification of a small fraction of the relevant proteins [42, 43] . It is quite interesting that we find that transfection of HEK-293 cells with an expression vector for a ubiquitin-LDB1 fusion lead to increased levels of the LDB1 portion of the fusion protein, despite the fact that the Nterminal ubiquitin moiety appeared to be rapidly removed. The ubiquitin-LDB1 fusion construct introduces no additional amino acid between the C-terminal glycine residue of ubiquitin and the initiation methionine residue of LDB1. As the second amino acid of LDB1 is leucine, a relatively large amino acid, the Nterminal methionine residue is not predicted to be removed [44] . Thus, after de-ubiquitination of the ubiquitin-LDB1 fusion, the resulting LDB1 protein should have the same amino acid sequence as protein produced by the expression vector encoding the unfused LDB1. These findings are consistent with the possibility that transient mono-ubiquitination induces a long-lasting change in LDB1 that blocks poly-ubiquitination and degradation. For instance, interaction with ubiquitin-binding protein might lead to changes in subcellular location so that LDB1 was not available for poly-ubiquitination. There are some similarities in the present study of LDB1 to other recent studies of the ubiquitination of transcription factors. It was found that RNF12 binds and ubiquitinates the oestrogen receptor α, but does not stimulate degradation of the receptor [45] . The E3-ubiquitin ligase RNF31 can mono-ubiquitinate and stabilize the transcriptional regulatory factor DAX-1 [46] . Mono-ubiquitination is known to control processes such as membrane transport, protein localization and protein-protein interactions [41, 43, 47, 48] . In addition there is evidence that mono-ubiquitination can enhance transcription factor activity [49, 50] .
Perhaps the most interesting question about RNF12 and LDB1 concerns a possible physiological role of RNF12 to increase LDB1 expression. Previous studies have shown that RNF12 can decrease LDB1 protein levels due to the action of RNF12 working as a ubiquitin ligase leading to poly-ubiquitination and degradation of LDB1 [17, 18] . The present study has confirmed that, in some cells, RNF12 can lead to LDB1 degradation in an RNF12 RING-finger-dependent manner. Our studies examining expression of LDB1-K134R in Xenopus embryos demonstrate that mutation of this residue enhances the level of LDB1. This finding is consistent with a net effect in the whole embryo of polyubiquitination at Lys 134 leading to degradation of LDB1. However, the present studies also demonstrate that, in HEK-293 cells, expression of RNF12 has the opposite effect, enhancing LDB1 levels. The present findings raise the possibility that, in some cells during development or under particular conditions, RNF12 does not cause LDB1 degradation, but rather stabilizes LDB1. This would provide an additional level of LDB1 regulation. We have been unable to determine whether endogenous RNF12 is required to enhance LDB1 expression in HEK-293 cells, as knockdown experiments were not informative. Perhaps future studies of mice with genetic disruption of RNF12 will be informative. If RNF12 does play a physiological role in some cells or tissues to enhance LDB1 levels, it would be likely to have substantial biological significance.
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